Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.

Saved in:
Bibliographic Details
Title: Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.
Authors: Marín-Jiménez JA; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Oliva M; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain.; Oncobell Program - Bellvitge Biomedical Research Institute (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain., Peinado Martín P; Head and Neck Cancer Unit, Department of Medical Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos, Madrid, Spain., Cabezas-Camarero S; Head and Neck Cancer Unit, Department of Medical Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos, Madrid, Spain., Plana Serrahima M; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Vázquez Masedo G; Department of Radiation Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos (IdISCC), Madrid, Spain., Lozano Borbalas A; Department of Radiation Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Cabrera Martín MN; Department of Nuclear Medicine, Hospital Universitario Clínico San Carlos - IdISCC, Madrid, Spain., Esteve A; Department of Medical Oncology, Catalan Institute of Oncology (ICO-Badalona), B-ARGO group, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain.; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat) - Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain., Iglesias Moreno MC; Otolaryngology - Head and Neck Surgery Department, Hospital Universitario Clínico San Carlos e- IdISCC, Madrid, Spain., Vilajosana Altamis E; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Arribas Hortigüela L; Clinical Nutrition Unit, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain., Taberna Sanz M; Head and Neck Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO - L'Hospitalet de Llobregat), Barcelona, Spain.; Oncobell Program - Bellvitge Biomedical Research Institute (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain., Pérez-Segura P; Head and Neck Cancer Unit, Department of Medical Oncology, Hospital Universitario Clínico San Carlos - Instituto de Investigación Sanitaria Hospital Clínica San Carlos, Madrid, Spain., Mesía R; Department of Medical Oncology, Catalan Institute of Oncology (ICO-Badalona), B-ARGO group, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Barcelona, Spain.
Source: Frontiers in oncology [Front Oncol] 2022 Jul 22; Vol. 12, pp. 953020. Date of Electronic Publication: 2022 Jul 22 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2022.953020